Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers

被引:51
|
作者
Carlson J.J. [1 ]
Gries K.S. [1 ]
Yeung K. [1 ]
Sullivan S.D. [1 ]
Garrison Jr. L.P. [1 ]
机构
[1] Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195-7630
关键词
National Health Service; Health Technology Assessment; Administrative Burden; Conditional Coverage; Pharmaceutical Benefit Advisory Committee;
D O I
10.1007/s40258-014-0093-x
中图分类号
学科分类号
摘要
Our objective was to identify and characterize publicly available cases and related trends for performance-based risk-sharing arrangements (PBRSAs). We performed a review of PBRSAs over the past 20 years (1993-2013) using available databases and reports from colleagues and healthcare experts. These were categorized according to a previously published taxonomy of scheme types and assessed in terms of the underlying product and market attributes for each scheme. Macro-level trends were identified related to the timing of scheme adoption, countries involved, types of arrangements, and product and market factors. Our search yielded 148 arrangements. From this set, 65 arrangements included a coverage with an evidence development component, 20 included a conditional treatment continuation component, 54 included a performance-linked reimbursement component, and 42 included a financial utilization component. Each type of scheme addresses fundamental uncertainties that exist when products enter the market. The pace of adoption appears to be slowing, but new countries continue to implement PBRSAs. Over this 20-year period, there has been a consistent movement toward arrangements that minimize administrative burden. In conclusion, the pace of PBRSA adoption appears to be slowing but still has traction in many health systems. These remain a viable coverage and reimbursement mechanism for a wide range of medical products. The long-term viability and growth of these arrangements will rest in the ability of the parties to develop mutually beneficial arrangements that entail minimal administrative burden in their development and implementation. © 2014 Springer International Publishing.
引用
收藏
页码:231 / 238
页数:7
相关论文
共 37 条
  • [31] Can't Get No Satisfaction? Will Pay for Performance Help? Toward an Economic Framework for Understanding Performance-Based Risk-Sharing Agreements for Innovative Medical Products
    Towse, Adrian
    Garrison, Louis P., Jr.
    PHARMACOECONOMICS, 2010, 28 (02) : 93 - 102
  • [32] ROLE OF CLINICAL PHARMACIST IN OPTIMIZING REIMBURSEMENT ORIGINATING FROM PERFORMANCE-BASED RISK-SHARING ARRANGEMENTS: THE EXPERIENCE OF THE UNIVERSITY HOSPITAL "G. MARTINO" FROM MESSINA, ITALY
    Polimeni, G.
    Isgro, V
    Aiello, A.
    D'Ausilio, A.
    D'Addetta
    Cuzzocrea, S.
    Caputi, A. P.
    Toumi, M.
    VALUE IN HEALTH, 2016, 19 (07) : A756 - A756
  • [33] Economic Impact of Coverage Expansion for Non-invasive Prenatal Testing Through a Performance-Based Risk-Sharing Agreement
    Quinlan, Taryn A. G.
    Schroeder, Brock
    Kwon, Sue
    Barlow, Jane F.
    Sherman, Michael S.
    Anderson, Heather D.
    Wright, Garth
    McQueen, R. Brett
    PHARMACOECONOMICS-OPEN, 2021, 5 (03) : 449 - 458
  • [34] LINKING PAYMENT AND HEALTH OUTCOMES: A SYSTEMATIC REVIEW AND TAXONOMY OF PERFORMANCE-BASED HEALTH OUTCOMES AGREEMENTS BETWEEN HEALTH CARE PAYERS AND MANUFACTURERS
    Carlson, J. J.
    Sullivan, S. D.
    Garrison, L. P.
    Neumann, P. J.
    Veenstra, D. L.
    VALUE IN HEALTH, 2009, 12 (03) : A90 - A90
  • [35] Economic Impact of Coverage Expansion for Non-invasive Prenatal Testing Through a Performance-Based Risk-Sharing Agreement
    Taryn A. G. Quinlan
    Brock Schroeder
    Sue Kwon
    Jane F. Barlow
    Michael S. Sherman
    Heather D. Anderson
    Garth Wright
    R. Brett McQueen
    PharmacoEconomics - Open, 2021, 5 : 449 - 458
  • [36] AGREEMENT BETWEEN FDA APPROVED DRUG LABEL AND PERFORMANCE BASED RISK-SHARING ARRANGEMENT ENDPOINTS
    Pham, N. N.
    Carlson, J. J.
    VALUE IN HEALTH, 2018, 21 : S119 - S119
  • [37] THE ROLE OF PERFORMANCE-BASED RISK-SHARING AGREEMENTS IN MINIMISING PAYER UNCERTAINTY WHEN STANDARD OF CARE IS NOT CLEARLY DEFINED; THE EXAMPLE OF CROHN'S DISEASE RELATED COMPLEX PERIANAL FISTULAS
    Schmetz, A.
    Kaur, S.
    Petrakis, I
    Agboton, C.
    Zouraq, Azzabi, I
    Minda, K.
    Rawson, K.
    Campbell-Hill, S.
    Baumgart, D. C.
    VALUE IN HEALTH, 2018, 21 : S148 - S148